Neutral or Detrimental Effects of TREM2 Agonist Antibodies in Preclinical Models of Alzheimer’s Disease and Multiple SclerosisAinhoa Etxeberría, Christopher J. Bohlen, Jose Imperio et al.|Journal of Neuroscience|2024Cited by 28
Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b <scp>OCARINA</scp> I studyScott D. Newsome, Robert A Bermel, Lawrence Goldstick et al.|Annals of Clinical and Translational Neurology|2024Cited by 3